1202490-65-0Relevant articles and documents
Triazolopyridines as selective JAK1 inhibitors: From hit identification to GLPG0634
Menet, Christel J.,Fletcher, Stephen R.,Van Lommen, Guy,Geney, Raphael,Blanc, Javier,Smits, Koen,Jouannigot, Nolwenn,Deprez, Pierre,Van Der Aar, Ellen M.,Clement-Lacroix, Philippe,Lepescheux, Liên,Galien, René,Vayssiere, Béatrice,Nelles, Luc,Christophe, Thierry,Brys, Reginald,Uhring, Muriel,Ciesielski, Fabrice,Van Rompaey, Luc
, p. 9323 - 9342 (2015/01/09)
Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function. Blockade of the JAK-STAT pathway with a small molecule has been shown to provide therapeutic immunomodulation. Having identified
NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES.
-
Page/Page column 47, (2010/04/03)
Novel [l,2,4]triazolo[l,5-a]pyridine compounds are disclosed that have a formula represented by the Formula I. The compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non- limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.
